БИОМАРКЕРЫ ЛЕКАРСТВЕННОЙ НЕФРОТОКСИЧНОСТИ
https://doi.org/10.17650/1726-9784-2015-14-3-3-18
Аннотация
Применение противоопухолевых препаратов, особенно на основе платины, связано с токсическим поражением различных здоровых тканей и органов, включая почки. Среди них цисплатин занимает одно из ведущих мест и обладает наибольшей нефротоксичностью, которую в течение многих лет оценивали по уровню сывороточного креатинина и азота мочевины крови. Однако эти маркёры обладают рядом существенных недостатков и не обеспечивают раннего обнаружения ОПП. Для идентификации ранних этапов ОПП нужны новые, более информативные маркёры, которые свидетельствовали бы о появлении начальных признаков поражения очень рано и независимо от фильтрационной функции почек. В обзоре представлены характеристики современных, перспективных маркёров раннего повреждения почек. Особое внимание уделено панели маркёров, рекомендуемых для доклинического изучения потенциальной нефротоксичности лекарств-кандидатов для передачи на клинические испытания. Приведены данные исследований о роли биомаркёров в ранней диагностике ОПП, вызванных цисплатином и его аналогами. Использование ROC-анализа в этих исследованиях показало, что новые маркёры обладают большей чувствительностью и специфичностью, чем традсывороточный креатинин и азот мочевины крови и могут быть использованы для диагностики и мониторинга почечных поражений, вызванных лекарственными препаратами.
Ключевые слова
нефротоксичность,
цисплатин,
биомаркёры,
диагностика,
nephrotoxicity,
cisplatin,
biomarkers,
diagnostics
Об авторах
Татьяна Владимировна Осипова
ФГБНУ «РОНЦ им. Н.Н. Блохина» МЗ РФ
Россия
Россия
В. М. Бухман
ФГБНУ «РОНЦ им. Н.Н. Блохина» МЗ РФ
Россия
Россия
Список литературы
1. Абаев В.М., Любимова Н.В., Михайлова Л.М. и др. Экспериментальное исследование токсического действия циклоплатама на почки и печень // Вестник РОНЦ им. Н.Н.Блохина РАМН. - 2000. - №3. - С. 43-51.
2. Вельков В.В., Резникова О.И. Современная лабораторная диагностика ренальных патологий: от ранних стадий до острой почечной недостаточности // Лабораторная диагностика. - 2010. - Т. 4, № 54. - С. 59-65.
3. Купчан Д.З. Характеристика отдельных противоопухолевых препаратов. Переводчикова Н.И. (ред.) Руководство по химиотерапии опухолевых заболеваний. 3-е изд., доп. и пер. - М.: Практическая медицина, 2011. - С. 72-119.
4. Кушлинский Н.Е., Любимова Н.В., Дурнов Л.А. и др. Значение ферментурии в оценке нефротоксичности противоопухолевых химиотерапии у детей //БЭБМ- 1997. - №10. - С. 446-50.
5. Любимова Н.В., Топчиева С.В., Аверинова С.Г. и др. Современные методы диагностики и мониторинга нефротоксичности при проведении противоопухолевой химиотерапии производными платины // БЭБМ. - 2000. - № 9. - С. 317-23.
6. Поддубная И.В., Орёл Н.Ф. Побочные реакции и осложнения лекарственной терапии. Поражение мочевыводящей системы. Переводчикова Н.И. (ред.) Руководство по химиотерапии опухолевых заболеваний. 3-е изд., доп. и пер. - М.: Практическая медицина, 2011. - С. 425-46; 437-9.
7. Amin R.P., Vickers A.E., Sistare F. et al. Identification of putative gene based markers of renal toxicity // Environ Health Perspect. - 2004. - 112(4) - P. 465-79.
8. Bailly V., Zhang Z., Meier W. et al. Shedding of kidney injury molecule 1 a putative adhesion protein involved in renal regeneration // J.Biol.Chem. - 2002. - 277(42). - P. 39739-48.
9. Basnakian A.G. Netrin 1: universal biomarker for acute kidney injury // Am.J.Physiol.Renal.Physiol. - 2008. - 294(4). - P. F729-30.
10. Bondiou M.T., Bourbouze R., Bernard M. et al. Inhibition of A and B N-acetyl-beta-D-glucosaminidase urinary isoenzymes by urea // Clin Chim Acta. - 1985. - 149(1). - P. 67-73.
11. Bonventre J.V., Vaidya V.S., Schmouder R. et al. Next-generation biomarkers for detecting kidney toxicity //Nat.Biotechnol. - 2010. - 28(5). - P. 436-40.
12. Boulikas T., Vougiouka M._Cisplatin and platinum drugs at the molecular level // Oncol.Rep. - 2003. -10(6). - P. 1663-82.
13. Chinery R., Poulsom R., Elia G. et al. Expression and purification of a trefoil peptide motif in a beta-galactosidase fusion protein and its use to search for trefoil-binding sites // Eur.J.Biochem. - 1993. - 212. -P. 557-63.
14. Chiusolo A., Defazio R., Zanetti E. et.al. Kidney injury molecule 1 expression in rat proximal tubule after treatment with segment-specific nephrotoxicants: A tool for early screening of potential kidney toxicity // Toxicol Pathology. - 2010. - 38(3). - P. 338-45.
15. Coca S.G., Parikh C.R. Urinary biomarkers for acute kidney injury: perspectives on translation // Clin. J. Am. Soc. Nephrol. - 2008. - 3(2). - P. 481-90.
16. Correa-Roffer R. Induction of clasterin in tubules of nephritic rats // J.Am.Soc.Nephrol. - 1998. - 9. - P. 33-7.
17. Cristofori P., Zanetti E., Fregona D. et al. Renal proximal tubule segment-specific nefrotoxicity: An review on biomarkers and histopatology // Toxicologic Pathology. - 2007. - 35. - P. 270-5.
18. Critical Path Institute. Letter of support for two rodent kidney safety biomarkers // 2014. http://c-path. org/programs/pstc/regulatory-successes/
19. de Geus H.R., Betjes M.G., Bakker J. Biomarkers for prediction of acute kidney injury: narrative review on current status and future challenges // Clin.Kidney J. - 2012. - 5. - P. 102-8.
20. Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury // Expert.Opin.Med.Diag. - 2008. - 2(4). - P. 387-98.
21. Devarajan P. Emerging biomarkers for the early detection of acute kidney injury // Nephrology. - 2010. -5(2). - P. 38-44.
22. Devarajan P., Tarabishi R., Mishra J. et al. Low renal toxicity of lipoplatin compared to cisplatin in animals //Anticancer Res. - 2004. - 24 (4). - P. 2193-200.
23. Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis // J. Kidney Dis. - 2002. - 40(2). - P. 221-6.
24. Dieterle F., Marrer E., Suzuki E. et al. Monitoring kidney safety in drug development: emerging technologies and their implication // Curr.Opin.Drug Discov.Devel. - 2008. - 11(1). - P. 60-71.
25. Dieterle F., Perentes E., Cordier A. et.al. Urinary clasterin, ß2-micriglobulin and total protein as markers to detect drug-induced kidney injury // Nat.Biotethnol. - 2010. - 28. - P. 463-9.
26. Dodiya H., Mukul J., Goswami S. Study of urinary biomarkers for nephrotoxicity in Wistar rats // J.Pharmacol.Toxicol. - 2011. - 6(6). - P. 571-9.
27. Falkenberg F.W., Hildebrand H., Lutte L. et al. Urinary antigens as markers of papillary toxicicity: I. Identification and characterization of rats kidney papillary antigens with monoclonal antibodies // Arch. Toxicol. - 1996. - 71(1-2). - P. 80-92.
28. Faubel S., Lewis E.C., Reznikov L. et al. Cisplatin induced acute renal failure is associated with an increase in the cytokines interlekin IL-1ß, IL18, IL6, and neuthil infiltration in the kidney // J.Pharmacol.Exp.Ther. -2007. - 322 (1). - P. 8-15.
29. Feinfeld D.A., Fuh V.L., Safirstein R. Urinary glutathione-S-transferase in cisplatin nephrotoxicity in the rat // J Clin Chem Clin Biochem. - 1986. - 24(8). - P. 529-32.
30. Fuchs T.C., Hewitt P. Biomarkers for drug-induced damage and nephrotoxicity. An overview for applied toxicology // The AAPS Journal. - 2011. - 13(4). - P. 615-31.
31. Gaspari F., Cravedi P., Mandalà M. et al. Predicting cisplatin-induced acute kidney injury neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study // Nephron.Clin.Pract. - 2010. -115(2). - P. 154-60.
32. Gautier J.C., Riefke B., Walter J. et al. Evaluation of new biomarkers of nephrotoxicity in two strains of rat treated with cisplatin // Toxicology Pathology. - 2010. - 38(6). - P. 943-56.
33. Han W.K., Bailly V., Abichandani R. et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury kidney // Kidney International. - 2002. - 62. - P. 237-44.
34. Han W.K., Waikar S.S., Johnson A. et al. Urinary biomarkers in the early diagnosis of acute kidney injury // Kidney International. - 2008. - 73. - P. 863-9.
35. Harpur E., Ennulat D., Hoffman D. et al. Biological quantification of biomarkers of chemical-induced renal toxicity in two strains of male rat // Toxicological Sciences. - 2011. - 122(2). - P. 235-52.
36. Harrison D.J., Kharbanda R., Cunningham D.S. et al. Distribution of glutathione-S-transferase isoenzymes in human kidney: basis for possible markers of renal injury // J. Clin.Pathol. - 1989. - 42. - P. 624-8.
37. Hofmeister R., Bhargava A.S., Günzel P. Value of enzyme determinations in urine for the diagnosis of nephrotoxicity in rats // Clin. Chim. Acta. - 1986. - 160(2). - P. 163-7.
38. Honore P.M., Joannes-Boyau O., Boer W. et al. The early biomarker of acute kidney injury: in search of the Holy Grall //Intensive Care Med. - 2007. - 33. - P. 1866-8.
39. Huang Q., Dunn R.T., Jayadev S. et al. Assessment of cisplatin-induced nephrotoxicity by microarray technology // Toxicol. Sci. - 2001. - 63(2). - P. 196-207.
40. Ichimura T., Hung C.C., Yang S.A. et al. Kidney injury molecule-1 a tissue and urinary biomarker for nephrotoxicant-induced renal injury //Am.J.Physiol.Renal.Physiol. - 2004. - 286. - P. F552-63.
41. Khan E., Batuman V., Lertora J.J. Emergence of biomarkers in nephropharmacology // Biomark. Med. - 2010. - 4(6). - P. 805-14.
42. Kilty C., Doyle S., Hassett B. et al. Glutation-S- transferases as biomarkers of organ damage: application of rodent and canine Г-S-T enzyme immunoassays // Chem.Biol.Interact - 1998. - 111-112. - P. 123-5.
43. Kondo C., Minowa Y., Uehara T. et al. Identification of genomic biomarkers for concurrent diagnosis of drug induced renal tubular injury using a large-scale toxicogenomic database // Toxicology. - 2009. -265(1-2). - P. 15-26.
44. Kos F.T., Sendur M.A., Aksoy S. et al. Evaluation of renal function using the level of Neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy // Asian Pac. J. Cancer Prev. - 2013. - 14(2). - P. 1111-4.
45. Kurschel E., Metz-Kurschel U., Niederle N. et al. Investigations on the subclinical and clinical nephrotoxicity of interferon-a2B in patients with myeloproliferative syndromes //Ren.Fail. - 1991. - 13. - P. 87-93.
46. Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury // Blood Purif - 2010. - 29. - P. 357-65.
47. Litterst C.L., Gram T.E., Dedrick R.L. et al. Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs // Cancer Res. - 1976. - 36(7 PT 1). P. 2340-4.
48. Litterst C.L, LeRoy A.F., Guarino A.M. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals // Cancer Treat Rep. - 1979. - 63(9-10). - P. 1485-92.
49. Lock E.A. Toxicolocical highlight. Sensitive and early markers of renal injury. Where are we and what is the way forward? // Toxicological Sciences. - 2010. - 116(1). - P. 1-4.
50. Ludwig T., Riethmüller C., Gekle M. et al. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport // Kidney International. - 2004. - 66. - P. 196-202.
51. Maatman R.G., van de Westerlo E.M., van Kuppevelt T.H. et al. Molecular identification of the liver and heart-type fatty acid-binding protein in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction //Biochem.J. -1992. - 288(Pt.1). -P. 285-90.
52. Mårtensson J., Martling C.R., Bell M. Novel biomarkers of acute kidney injury and failure: clinical applica bility // Brit.J.Anestesia. - 2012. - 109(6). - P. 843-50.
53. Mc Duffie J.E., Ma J.Y., Sablab M. et al. Time course of renal proximal tubule injury reversal and related biomarker changes in rats following cisplatin administration // Int.J. Toxicol. - 2013. - 32(4). - P. 251-60.
54. Mishra J., Ma Q., Prada A. et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal inury // J.Am.Soc.Nephrol. -2003. -14(10). -P. 2534-43.
55. Mishra J., Mori K., Ma Q. et al. Neutrophil gelatinase-associated lipocalin a novel early urinary biomarkers for cisplatin nephrotoxicity// Am.J.Nephrol. -2004. -24(3). -P. 307-15.
56. Mishra J., Mori K., Ma Q._et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin // Am.J.Soc.Nephrol. -2004. -15. -P. 3073-82.
57. Mishra J., Ma Q., Kelly C. et al. Kidney NGAL is a novel early marker of acute injury following transplantation // Pediator.Nephrol. - 2006. - 21. - P. 856-63.
58. Moran S.M., Myers B.D. Course of acute renal of feature studied by a model of creatinine kinetics // Kidney International. - 1985. - 27. - P. 928-37.
59. Naidu S.G., Lee F.T. Contrast nephrotoxicity: predictive value of urinary enzyme markers in a rat model // Acad.Radiol. - 1994. - 1(1). - P. 3-9.
60. Nasri H. Comment on: A model for prediction of cisplatin-induced nephrotoxicity by kidney weight in experimental rats // J.Res.Med. Sciences. - 2013. - 18(12). - P. 1119-200.
61. Negishi K., Noiri E., Doi K._et al. Monitoring urinary L-type fatty acid binding protein predicts histological severity of acute kidney injury //Amer.J. Pathology. -2009. -174(4). -P. 1154-9.
62. Osman N.M., Litterst C.L. Effect of probenecid and N'-methylnicotinamide on renal handling of cisdichlorodiammineplatinum-II in rats // Cancer Lett. - 1983. - 19(1). - P. 107-11.
63. Ostermann M., Philips B.J., Forni L.G. Clinical review. Biomarkers of acute kidney injury: Where are we now? // Critical Care. - 2012. - 16. - P. 233.
64. Parikh C.R., Jani A., Melnikov V.Y._et al. Urinary IL18 is a marker of human acute tubular necrosis // Am.J.Kidney Dis. - 2004. - 43. - P. 405-14.
65. Pasetto L.M., D'Andrea M.R., Brandes A.A. et al. The development of platinum compounds and their possible combination // Crit.Rev.Oncol.Hematol. -2006. -60. -P. 59-75.
66. Perazella M.A., Moeckel G.W. Nephrotoxicity from chemotherapeutic agents: clinical manifestations pathobiology and prevention therapy // Semin. Nephrology. -2010. -30(6). -P. 570-81.
67. Pinches M., Betts C., Bickerton S. et.al. Evaluation of novel renal biomarkers with cisplatin model of kidney injury: gender and dosage differences // Toxicol.Pathol. - 2012. - 40. - P. 522-33.
68. Portilla D., Li S., Nagothu K.K. et al. Metabolomic study of cisplatin-induced nephrotoxicity //Kidney Int. - 2006. -69. -P. 2194-204.
69. Portilla D., Schnackenberg L., Beger R.D. Metabolomics as an extension of proteomic analysis: study of acute kidney injury // Semin Nephrol. - 2007 - 27. - P. 609-20.
70. Price R.G. The role NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity // Clin.Nephrol. - 1992. - 38(suppl.1). - P. S14-9.
71. Reeves W.B., Kwon O., Ramesh G. Netrin 1 and kidney injury. II. Netrin 1 as an early biomarkers of acute kidney injury //Am.J.Physiol.Renal.Phisiol. -2008. -294. -P. F731-8.
72. Rosenberg M.E., Silkensen J. Clusterin: physiologic and phatophysiologic considerations // Int.J.Biochem.Cell.Biol. -1995. -27. -P. 633-45.
73. Safirstein R., Winston J., Goldstein M. et al. Cisplatin nephrotoxicity //Am.J. Kidney Dis. - 1986. - 8. - P. 356-67.
74. Sahni V., Choudhury D., Ahmed Z._et al. Chemotherapy-associated renal dysfunction //Nat.Rev.Nephrol. - 2009. -5(8). -P. 450-62.
75. Saleena U.V., Athiyamaan M., Vadhiraja B.M. et al. Urinary a-glutathione-s-transferase variations in cisplatin treated cancer patients with and without kidney injury // Internat.Conf on Bioscience, Biochemistry, Bioinformatics. IPCBEE. - 2012 - 31. - P. 32-9.
76. Schentag J.J. Specificity of renal tubulare damage criteria for aminoglycoside nephrotoxicity in criticcaly ill patients// J.Clin.Pharmacol. - 1983. - 23(10). - P. 473-83.
77. Schmidt-Ott K.M., Mori K., Kalandadze A. et al. Neutrophil gelatinase-associated lipocalin- mediated iron traffic in kidney epithelia//Curr.Opin.Nephrol.Hypertens. -2006. -15(4). -P. 442-9.
78. Taguchi T., Razzaque M.S. Cisplatin-associated nephrotoxicity and pathological events. Razzague MS, Taguchi T (eds): Cellular stress responses in renal diseases. Contrub.Nephrol. Basel: Karger, 2005. - 148. - P. 106-20.
79. Tesch G.H. Serum and urine biomarkers of kidney disease: A pathophysiological perspective // Nephrology. - 2010. - 15. - P. 609-16.
80. Thompson K.L., Afshari C.A., Amin R.P. et al. Identification of platform-independent gene expression markers of cisplatin nephrotoxicity // Enviromental Health Perspectives. - 2004. - 119(4). - P 488-94.
81. Thukral S.K., Nordone P.J., Hu R. et al. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers // Toxicol. Pathol. -2005. -33. -P. 343-55.
82. Tonomura Y., Tsuchiya N., Torii M. et al. Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats // Toxicology. -2010. -273. - P. 53-9.
83. Trevisan A., Cristofori P., Fanelli G.jGlutamine syntetase activity in rat urine as sensitive marker to detect S3 segment specific injury of proximal tubule induced by xenobiotics // Arch. Toxicol. - 1999. - 73(4-5). -P. 255-62.
84. Uchida K., Gotoh A. Measurement of cystatin C and creatinine in urine // Clin. Chem.Acta. - 2002. - 323. -P. 121-8.
85. Uehara T., Watanabe H., Itoh F. et al. Nephrotoxicity of a novel antineoplastic platinum complex nedaplatin: a comparative study with cisplatin in rats// Arch.Toxicol. -2005. - 79(8). -P. 451-60.
86. Uehara T., Yamate J., Torii M. et al. Comparative nephrotoxicity of cisplatin and nedaplatin mechanisms andhistopathological characteristic//J.Toxicol.Patol. -2011. -24. -P. 87-94.
87. Vaidya V.S., Ramirez V., Ichimura T. et al. Urinary kidney injury molecule 1: a sensitive quantitative biomarker for early detection of kidney tubular injury // Am.J.Physiol.Renal.Physiol. - 2006. - 290(2). - P. F517-29.
88. Vaidya V.S., Ferguson M.A., Bonventre J.V. Biomarkers of acute kidney injury // Annu.Rev.Pharmacol.Toxicol. -2008. -48. -P. 463-8.
89. Vaidya V.S., Ozer J.S., Frank D. et al. Kidney injury molecule 1 outperforms traditional biomarkers of kidney injury in multi-site preclinical biomarker qualification studies // Nat.Biotechnol. - 2010. - 28(5). - P. 478-85.
90. Vinken P., Starckx S., Barale-Thomas E. et al. Tissue kim-1 and urinary clasterin as early indicators of cisplatin-induced acute kidney injury in rats // Toxcol.Pathol. -2012. -40(7). -P. 1049-62.
91. Westhuyzen J., Endre Z.H., Reece G. et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit //Nephrol Dial Transplant. - 2003. - 18(3). - P. 543-51.
92. Whiting P.H., Brown P.A. The relation between enzymuria and kidney enzyme activities in experimental gentamicin nephrotoxicity//Ren.Tail. -1996. -18(6). -P. 899-909.
93. Wolfgang G.H., Dominick M.A., Walsh K.M. et al. Comparative nephrotoxicity of a novel platinum compound cisplatin and carboplatin in male Wistar rats//Fund.Appl.Toxicology. -1994. -22(1). -P. 73-9.
94. Yamate J., Tatsumi M., Nakatsuji S. et al. Immunohistochemical observations on the kinetics of macrophages and myofibroblasts in rat renal interstitial fibrosis induced by cis-diamminedichloroplatinum // J. Compar. Phatol. - 1995. - 112(1). - 27-39.
95. Yano R., Golbar H.M., Izawa T. et al. Participation of bone morphogenetic protein (BMP)-6 and osteopontin in cisplatin (CDDP)-induced rat renal fibrosis // Exp Toxicol Pathol. - 2015. - 67(2). -P. 99-107.
96. Yu Y., Jin H., Holder D._et al. Urinary biomarkers trefoil factor 3 and albumine enable early detection of kidney tubular injury//Nat. Biotechnol. -2010. -28(5). -P. 470-7.
97. Zhou Y., Vaidya V.S., Brown R.P. et al. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium // Toxicol Sci. - 2008. - 101(1). - P. 159-70.
Рецензия
Для цитирования:
Осипова Т.В., Бухман В.М. БИОМАРКЕРЫ ЛЕКАРСТВЕННОЙ НЕФРОТОКСИЧНОСТИ. Российский биотерапевтический журнал. 2015;14(3):3-18. https://doi.org/10.17650/1726-9784-2015-14-3-3-18
For citation:
Osipova T.V., Bukhman V.M. BIOMARKERS OF DRUG NEPHROTOXICITY. Russian Journal of Biotherapy. 2015;14(3):3-18. (In Russ.) https://doi.org/10.17650/1726-9784-2015-14-3-3-18
Просмотров:
561
Послать статью по эл. почте 
